Jonathan Cohen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Jonathan Cohen has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Martin John Llewelyn
Department of Global Health and Infection, Brighton and Sussex Medical School, University of Sussex, Falmer, UK
2 shared publications Steven Opal
Infectious Disease Division, Alpert Medical School of Brown University, Providence, RI, USA
2 shared publications- Thierry Calandra
Service of Immunology and Allergy, Department of Medicine and Department of Laboratory Medicine and Pathology, Center for Human Immunology Lausanne, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland
2 shared publications Alison Church
Department of Infectious Diseases, Imperial College School of Medicine, Division of Investigative Science, Hammersmith Hospital, London W12 ONN, UK
1 shared publication- Amanda L Taylor
Brighton and Sussex Medical School, Falmer, BN1 9PS, UK
1 shared publication Derek C Angus
Department of Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA, USA
1 shared publication
Latest Publications
- Open Access
- 18 March 2025
- Published by Frontiers Media SA in Frontiers in Science
- Vol. 3, 1560472
The challenge of sepsis
To paraphrase Jane Austen, it is a truth universally acknowledged that sepsis has been one of the most difficult and frustrating clinical challenges of the last 50 years. Despite literally thousands of scientific papers and tens of thousands of patients enrolled in clinical trials, the clinical syndrome that we call sepsis continues to be responsible for approximately 20% of all deaths worldwide (Meyer, 2024). Unlike some of the major infective challenges that are largely restricted to certain geographical regions-such as malaria in sub-Saharan Africa and the Far East, or gastrointestinal infections in South Asia-sepsis is a global threat, as recognized by the World Health Organization (WHO) in its 2017 Resolution (WHO 2017). It is a sobering thought that even the most advanced economies deploying sophisticated intensive care methods have made only modest inroads into reducing sepsis-related mortality.Why has this been so difficult?As Hancock et al. point out in their lead article (Hancock et al. 2025), sepsis is a prototypic syndrome with a bewildering array of symptoms and signs, a multitude of causes, and an impact that stretches from a relatively mild self-limiting illness to an acute, life-threatening disease. Little wonder then that it has proved so challenging. The difficulties in establishing a single epidemiological definition have made it almost impossible to enroll a homogeneous population into clinical trials and has greatly hindered the investigation of new treatments.Meanwhile, at the bedside, it is usually relatively junior clinical staff who struggle to recognize the condition at an early enough stage to start treatment early. Hancock et al. make the case that the use of systems immunology tools have the potential to dissect this heterogeneous population into specific subgroups-"endotypes"-early in the clinical presentation to help predict the disease course and select treatments that will specifically address the pathological molecular dysfunction. This approach-an example of the concept of precision medicine-will depend for its success on (at least) three elements. First, it requires that the "omic profile" is consistent and reproducible in terms of the clinical phenotype and the clinical and geographic context of the patient. This is still a work in progress; Garduno and others (Garduno, 2023) have helpfully reviewed the range of different approaches to creating stable endotypes. Secondly, it will be important to understand how these endotypes evolve longitudinally in individual patients, a point rightly emphasized by Hancock et al. One of the clinical challenges is that patients with sepsis present at widely differing points in their clinical course; we need to understand how the omic profile changes over time and how this should be interpreted. Finally, at a practical level, all of this depends on the availability of simple, widely available diagnostic tests that can used quickly and easily in emergency departments, and clearly this is still a long way off.There is also an interesting conceptual question as to whether omics-based endotypes are sufficient alone to adequately identify patients and allow specific therapeutic interventions.Garduno (Garduno, 2023) summarized a number of small clinical trials in which immunologic manipulations were deployed based on an immunophenotypical abnormality: thus far the outcomes have not been particularly successful. One component of the equation that seems missing at present is the causative organism, a point also made by others (Giamerellos-Bourboulis, 2024). While sepsis is in many respects a final common pathway of injury following infection, different bacteria (and viruses) lead to quite different clinical and immunologic effects. For instance, Streptococcus pyogenes, a Gram-positive bacterium, can be associated with a toxic shock-like syndrome attributed to a superantigen effect, while the Gram-negative Vibrio vulnificus is associated with sepsis and necrotizing skin lesions. The challenge will be to incorporate complex omics data together with clinical and microbiologic information into what one might call an individual "therapeutic prescription".Post-sepsis, long COVID, and chronic fatigue syndrome-one and the same?One of the most intriguing insights to emerge in the post-COVID era is the apparent similarity between three seemingly distinct conditions. Chronic fatigue syndrome (CFS; known also as myalgic encephalitis or post-viral syndrome) has long been recognized as a variable constellation of symptoms and signs that often, but not always, follows an acute viral infection such as Epstein Barr virus. Characterized by profound fatigue lasting many months, and sometimes years, and a myriad of inconsistent immunologic findings, it has long frustrated both clinicians and patients because of the lack of a single diagnostic test and the absence of any effective treatment. Post-sepsis syndrome (PSS), recognized more recently, refers to the physical and in particular the neurocognitive, and neuropsychological consequences following acute sepsis. Finally, long COVID (or post-COVID syndrome), one of the most consequential long-term effects of the pandemic, also shows a wide range of manifestations, including significant neuropsychiatric, cardiovascular, and autoimmune phenomena, associated with evidence of immune dysregulation, mitochondrial abnormalities, and effects on the microbiome (Fleischman-Struzek, 2024). Hancock and colleagues focus on the similarities between PSS and long COVID, and describe gene expression studies which distinguish patients with an uncomplicated course from those who go on to develop long COVID. They speculate that epigenetic mechanisms may influence the development of both syndromes. Once again it seems to be possible to identify endotypes-that is, transcriptional patterns that co-locate with clinical phenotypes to identify different responses to acute infection.The challenge here is to...
- 18 March 2025
- Published by Frontiers Media SA in Frontiers in Science
- Vol. 3, 1560472
Open AccessThe challenge of sepsis
To paraphrase Jane Austen, it is a truth universally acknowledged that sepsis has been one of the most difficult and frustrating clinical challenges of the last 50 years. Despite literally thousands of scientific papers and tens of thousands of patients enrolled in clinical trials, the clinical syndrome that we call sepsis continues to be responsible for approximately 20% of all deaths worldwide (Meyer, 2024). Unlike some of the major infective challenges that are largely restricted to certain geographical regions-such as malaria in sub-Saharan Africa and the Far East, or gastrointestinal infections in South Asia-sepsis is a global threat, as recognized by the World Health Organization (WHO) in its 2017 Resolution (WHO 2017). It is a sobering thought that even the most advanced economies deploying sophisticated intensive care methods have made only modest inroads into reducing sepsis-related mortality.Why has this been so difficult?As Hancock et al. point out in their lead article (Hancock et al. 2025), sepsis is a prototypic syndrome with a bewildering array of symptoms and signs, a multitude of causes, and an impact that stretches from a relatively mild self-limiting illness to an acute, life-threatening disease. Little wonder then that it has proved so challenging. The difficulties in establishing a single epidemiological definition have made it almost impossible to enroll a homogeneous population into clinical trials and has greatly hindered the investigation of new treatments.Meanwhile, at the bedside, it is usually relatively junior clinical staff who struggle to recognize the condition at an early enough stage to start treatment early. Hancock et al. make the case that the use of systems immunology tools have the potential to dissect this heterogeneous population into specific subgroups-"endotypes"-early in the clinical presentation to help predict the disease course and select treatments that will specifically address the pathological molecular dysfunction. This approach-an example of the concept of precision medicine-will depend for its success on (at least) three elements. First, it requires that the "omic profile" is consistent and reproducible in terms of the clinical phenotype and the clinical and geographic context of the patient. This is still a work in progress; Garduno and others (Garduno, 2023) have helpfully reviewed the range of different approaches to creating stable endotypes. Secondly, it will be important to understand how these endotypes evolve longitudinally in individual patients, a point rightly emphasized by Hancock et al. One of the clinical challenges is that patients with sepsis present at widely differing points in their clinical course; we need to understand how the omic profile changes over time and how this should be interpreted. Finally, at a practical level, all of this depends on the availability of simple, widely available diagnostic tests that can used quickly and easily in emergency departments, and clearly this is still a long way off.There is also an interesting conceptual question as to whether omics-based endotypes are sufficient alone to adequately identify patients and allow specific therapeutic interventions.Garduno (Garduno, 2023) summarized a number of small clinical trials in which immunologic manipulations were deployed based on an immunophenotypical abnormality: thus far the outcomes have not been particularly successful. One component of the equation that seems missing at present is the causative organism, a point also made by others (Giamerellos-Bourboulis, 2024). While sepsis is in many respects a final common pathway of injury following infection, different bacteria (and viruses) lead to quite different clinical and immunologic effects. For instance, Streptococcus pyogenes, a Gram-positive bacterium, can be associated with a toxic shock-like syndrome attributed to a superantigen effect, while the Gram-negative Vibrio vulnificus is associated with sepsis and necrotizing skin lesions. The challenge will be to incorporate complex omics data together with clinical and microbiologic information into what one might call an individual "therapeutic prescription".Post-sepsis, long COVID, and chronic fatigue syndrome-one and the same?One of the most intriguing insights to emerge in the post-COVID era is the apparent similarity between three seemingly distinct conditions. Chronic fatigue syndrome (CFS; known also as myalgic encephalitis or post-viral syndrome) has long been recognized as a variable constellation of symptoms and signs that often, but not always, follows an acute viral infection such as Epstein Barr virus. Characterized by profound fatigue lasting many months, and sometimes years, and a myriad of inconsistent immunologic findings, it has long frustrated both clinicians and patients because of the lack of a single diagnostic test and the absence of any effective treatment. Post-sepsis syndrome (PSS), recognized more recently, refers to the physical and in particular the neurocognitive, and neuropsychological consequences following acute sepsis. Finally, long COVID (or post-COVID syndrome), one of the most consequential long-term effects of the pandemic, also shows a wide range of manifestations, including significant neuropsychiatric, cardiovascular, and autoimmune phenomena, associated with evidence of immune dysregulation, mitochondrial abnormalities, and effects on the microbiome (Fleischman-Struzek, 2024). Hancock and colleagues focus on the similarities between PSS and long COVID, and describe gene expression studies which distinguish patients with an uncomplicated course from those who go on to develop long COVID. They speculate that epigenetic mechanisms may influence the development of both syndromes. Once again it seems to be possible to identify endotypes-that is, transcriptional patterns that co-locate with clinical phenotypes to identify different responses to acute infection.The challenge here is to...
- Open Access
- 28 March 2019
- Published by Wolters Kluwer Health in Dr. Sulaiman Al Habib Medical Journal
- Vol. 1 (1-2) , 23-26
Prospects for the Management of Sepsis in an Era of Personalised Medicine
Sepsis remains an unmet medical need, and sustained attempts by intensivists have indeed yielded an incremental improvement in outcomes. However, despite many attempts to introduce novel therapeutic molecules, there has been no step change in survival rates. Precision (or personalised) medicine (PM) has emerged in recent years as an approach that seeks to make use of person-specific, real-time data to choose a therapeutic regimen designed specifically for the individual patient. PM has been used most successfully in oncology where chemotherapy regimens can be tailored to specific cancer genotypes. This review considers the options for using PM to improve the outcome in sepsis. There are several challenges. The nature of omics technology is that it involves multiple analytes, each of which usually has a very modest effect; hence large numbers of patients need to be studied. Sophisticated bioinformatic analysis is required that is not suitable for routine clinical use. Sepsis is a fast-moving situation and it is likely that PM profiles would change quickly. This is a huge challenge, since it requires the physician to accurately place the patient in the appropriate cohort that is relevant to the test being used. Many septic patients have comorbidities that complicate data interpretation. Finally, the nature of PM is that it is designed for the individual patient, or at least for a homogeneous group of patients who share specific characteristics. As we have seen, that is difficult to achieve in sepsis, which is a heterogeneous condition. PM is likely to be harder to use in sepsis than in some other clinical settings.
- 28 March 2019
- Published by Wolters Kluwer Health in Dr. Sulaiman Al Habib Medical Journal
- Vol. 1 (1-2) , 23-26
Open AccessProspects for the Management of Sepsis in an Era of Personalised Medicine
Sepsis remains an unmet medical need, and sustained attempts by intensivists have indeed yielded an incremental improvement in outcomes. However, despite many attempts to introduce novel therapeutic molecules, there has been no step change in survival rates. Precision (or personalised) medicine (PM) has emerged in recent years as an approach that seeks to make use of person-specific, real-time data to choose a therapeutic regimen designed specifically for the individual patient. PM has been used most successfully in oncology where chemotherapy regimens can be tailored to specific cancer genotypes. This review considers the options for using PM to improve the outcome in sepsis. There are several challenges. The nature of omics technology is that it involves multiple analytes, each of which usually has a very modest effect; hence large numbers of patients need to be studied. Sophisticated bioinformatic analysis is required that is not suitable for routine clinical use. Sepsis is a fast-moving situation and it is likely that PM profiles would change quickly. This is a huge challenge, since it requires the physician to accurately place the patient in the appropriate cohort that is relevant to the test being used. Many septic patients have comorbidities that complicate data interpretation. Finally, the nature of PM is that it is designed for the individual patient, or at least for a homogeneous group of patients who share specific characteristics. As we have seen, that is difficult to achieve in sepsis, which is a heterogeneous condition. PM is likely to be harder to use in sepsis than in some other clinical settings.
- Open Access
- 10 April 2017
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 58, 110
International Society for Infectious Diseases: Position statement on the March for Science, April 22, 2017
- 10 April 2017
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 58, 110
Open AccessInternational Society for Infectious Diseases: Position statement on the March for Science, April 22, 2017
- 1 December 2016
- Published by SAGE Publications in Journal of the Royal College of Physicians of Edinburgh
- Vol. 46 (4) , 263-269
Current Clinical Controversies in the Management of Sepsis
Sepsis remains a challenging clinical problem requiring prompt diagnosis and optimal clinical management if the continuing high mortality is to be contained. In this brief review I consider four specific questions that are the subject of ongoing controversy. First, whether the new ‘Sepsis-3’ definitions will be helpful, in particular in improving diagnosis, or whether the rapid move towards precision medicine will make the definition redundant. Second, should we routinely use combinations of antibiotics for the empiric treatment of sepsis. Third, whether there is any clinical benefit in continuous rather than bolus administration of β-lactam antibiotics. Finally, whether there is good evidence that biomarkers such as procalcitonin can help reduce the duration of antibiotic therapy.
- 1 December 2016
- Published by SAGE Publications in Journal of the Royal College of Physicians of Edinburgh
- Vol. 46 (4) , 263-269
Current Clinical Controversies in the Management of Sepsis
Sepsis remains a challenging clinical problem requiring prompt diagnosis and optimal clinical management if the continuing high mortality is to be contained. In this brief review I consider four specific questions that are the subject of ongoing controversy. First, whether the new ‘Sepsis-3’ definitions will be helpful, in particular in improving diagnosis, or whether the rapid move towards precision medicine will make the definition redundant. Second, should we routinely use combinations of antibiotics for the empiric treatment of sepsis. Third, whether there is any clinical benefit in continuous rather than bolus administration of β-lactam antibiotics. Finally, whether there is good evidence that biomarkers such as procalcitonin can help reduce the duration of antibiotic therapy.
- Top Cited Papers
- 1 May 2015
- Published by Elsevier in The Lancet Infectious Diseases
- Vol. 15 (5) , 581-614
Sepsis: a roadmap for future research
- 1 May 2015
- Published by Elsevier in The Lancet Infectious Diseases
- Vol. 15 (5) , 581-614
Top Cited PapersSepsis: a roadmap for future research
- 1 January 2015
- Published by Elsevier in The Lancet Infectious Diseases
- Vol. 15 (1) , 5-6
Sepsis in children: some good news, some confusing news
- 1 January 2015
- Published by Elsevier in The Lancet Infectious Diseases
- Vol. 15 (1) , 5-6
Sepsis in children: some good news, some confusing news
- Open Access
- 26 March 2013
- Published by Springer Nature in Critical Care
- Vol. 17 (2) , R60
Sepsis biomarkers in unselected patients on admission to intensive or high-dependency care
Introduction: Although many sepsis biomarkers have shown promise in selected patient groups, only C-reactive protein and procalcitonin (PCT) have entered clinical practice. The aim of this study was to evaluate three promising novel sepsis biomarkers in unselected patients at admission to intensive care. We assessed the performance of pancreatic stone protein (PSP), soluble CD25 (sCD25) and heparin binding protein (HBP) in distinguishing patients with sepsis from those with a non-infective systemic inflammatory response and the ability of these markers to indicate severity of illness. Methods: Plasma levels of the biomarkers, PCT and selected inflammatory cytokines were measured in samples taken from 219 patients during the first six hours of admission to intensive or high dependency care. Patients with a systemic inflammatory response were categorized as having sepsis or a non-infective aetiology, with or without markers of severity, using standard diagnostic criteria. Results: Both PSP and sCD25 performed well as biomarkers of sepsis irrespective of severity of illness. For both markers the area under the receiver operating curve (AUC) was greater than 0.9; PSP 0.927 (0.887 to 0.968) and sCD25 0.902 (0.854 to 0.949). Procalcitonin and IL6 also performed well as markers of sepsis whilst in this intensive care unit (ICU) population, HBP did not: PCT 0.840 (0.778 to 0.901), IL6 0.805 (0.739 to 0.870) and HBP 0.607 (0.519 to 0.694). Levels of both PSP and PCT reflected severity of illness and both markers performed well in differentiating patients with severe sepsis from severely ill patients with a non-infective systemic inflammatory response: AUCs 0.955 (0.909 to 1) and 0.837 (0.732 to 0.941) respectively. Although levels of sCD25 did not correlate with severity, the addition of sCD25 to either PCT or PSP in a multivariate model improved the diagnostic accuracy of either marker alone. Conclusions: PSP and sCD25 perform well as sepsis biomarkers in patients with suspected sepsis at the time of admission to intensive or high dependency care. These markers warrant further assessment of their prognostic value. Whereas previously published data indicate HBP has clinical utility in the emergency department, it did not perform well in an intensive-care population.
- 26 March 2013
- Published by Springer Nature in Critical Care
- Vol. 17 (2) , R60
Open AccessSepsis biomarkers in unselected patients on admission to intensive or high-dependency care
Introduction: Although many sepsis biomarkers have shown promise in selected patient groups, only C-reactive protein and procalcitonin (PCT) have entered clinical practice. The aim of this study was to evaluate three promising novel sepsis biomarkers in unselected patients at admission to intensive care. We assessed the performance of pancreatic stone protein (PSP), soluble CD25 (sCD25) and heparin binding protein (HBP) in distinguishing patients with sepsis from those with a non-infective systemic inflammatory response and the ability of these markers to indicate severity of illness. Methods: Plasma levels of the biomarkers, PCT and selected inflammatory cytokines were measured in samples taken from 219 patients during the first six hours of admission to intensive or high dependency care. Patients with a systemic inflammatory response were categorized as having sepsis or a non-infective aetiology, with or without markers of severity, using standard diagnostic criteria. Results: Both PSP and sCD25 performed well as biomarkers of sepsis irrespective of severity of illness. For both markers the area under the receiver operating curve (AUC) was greater than 0.9; PSP 0.927 (0.887 to 0.968) and sCD25 0.902 (0.854 to 0.949). Procalcitonin and IL6 also performed well as markers of sepsis whilst in this intensive care unit (ICU) population, HBP did not: PCT 0.840 (0.778 to 0.901), IL6 0.805 (0.739 to 0.870) and HBP 0.607 (0.519 to 0.694). Levels of both PSP and PCT reflected severity of illness and both markers performed well in differentiating patients with severe sepsis from severely ill patients with a non-infective systemic inflammatory response: AUCs 0.955 (0.909 to 1) and 0.837 (0.732 to 0.941) respectively. Although levels of sCD25 did not correlate with severity, the addition of sCD25 to either PCT or PSP in a multivariate model improved the diagnostic accuracy of either marker alone. Conclusions: PSP and sCD25 perform well as sepsis biomarkers in patients with suspected sepsis at the time of admission to intensive or high dependency care. These markers warrant further assessment of their prognostic value. Whereas previously published data indicate HBP has clinical utility in the emergency department, it did not perform well in an intensive-care population.
- Open Access
- 14 November 2012
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 68 (3) , 490-491
Confronting the threat of multidrug-resistant Gram-negative bacteria in critically ill patients
The re-emergence of infection due to multidrug-resistant Gram-negative bacteria in critically ill patients presents particular challenges to clinicians, given the lack of a pipeline of new antibiotics active against these resistant strains. Infected patients have a worse outcome than non-infected patients, although the additional contribution of antimicrobial resistance is less easy to define. Newer and better antibiotics would be welcome, but are unlikely alone to make a major impact on clinical outcomes.
- 14 November 2012
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 68 (3) , 490-491
Open AccessConfronting the threat of multidrug-resistant Gram-negative bacteria in critically ill patients
The re-emergence of infection due to multidrug-resistant Gram-negative bacteria in critically ill patients presents particular challenges to clinicians, given the lack of a pipeline of new antibiotics active against these resistant strains. Infected patients have a worse outcome than non-infected patients, although the additional contribution of antimicrobial resistance is less easy to define. Newer and better antibiotics would be welcome, but are unlikely alone to make a major impact on clinical outcomes.
- 1 July 2012
- Published by Elsevier in The Lancet Infectious Diseases
- Vol. 12 (7) , 503-505
Sepsis studies need new direction
- 1 July 2012
- Published by Elsevier in The Lancet Infectious Diseases
- Vol. 12 (7) , 503-505
Sepsis studies need new direction
- Open Access
- 1 June 2009
- Published by Elsevier in Clinical Medicine
- Vol. 9 (3) , 256-257
Sepsis and septic shock: inching forwards
- 1 June 2009
- Published by Elsevier in Clinical Medicine
- Vol. 9 (3) , 256-257
Open AccessSepsis and septic shock: inching forwards